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Abstract
Background: Psoriasis is a chronic inflammatory immune disease with undefined pathogenesis. It is associated with T
cells, and the IL-23/IL17 axis is believed to be crucial in the pathogenesis. The present treatments have side effects that
influence the compliance of patients. Tea polyphenol is extracted from tea polyphenols, and its main active ingredient
is Epigallocatechin-3-gallate (EGCG), which has been shown to have antioxidant, anti-tumor, and anti-ultraviolet
radiation effects. Here, we aim to report that EGCG can inhibit imiquimod (IMQ)-induced psoriasis-like inflammation.
Methods: We used BALB/c mice, which were topically treated with IMQ for 6 consecutive days, as a psoriasis mouse
model. Topical application of EGCG and treatment with EGCG were conducted in the experiments. Then observed the
effects of the two methods on psoriasis-like mice dermatitis. Statistics are presented as the means ± standard error of
mean (SEM) and compared using unpaired two-tailed Student’s t tests or one-way ANOVA.
Results: Topical application of EGCG alleviated psoriasiform dermatitis, improved the skin pathological structure by
reduce the expression of epidermal PCNA, promoted the expression of caspase-14. Treatment with EGCG attenuated
skin inflammation, accompanied by reduced infiltrations of T cells; reduced percentages of CD11c+ DC in the
composition of immunocytes of spleens; reduced levels of interleukin (IL)-17A, IL-17F, IL-22, IL-23 and malondialdehyde
(MDA) in plasma; increased percentages of CD4+ T cells in the composition of immunocytes of spleens; and increased
bioactivities of superoxide dismutase (SOD) and catalase (CAT) in plasma.
Conclusions: All the results demonstrated that EGCG had anti-inflammatory, immune regulatory and antioxidant
effects. It is a promising intervention in psoriasis in the future.
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Background
Psoriasis, which is a T-cell-mediated chronic inflammatory
immune disease, is characterized by hyperproliferation and
poor differentiation of epidermal keratinocytes and massive
infiltration of leukocytes. The histological changes include
(1) a thickened epidermis from epidermal hyperplasia and
aberrant differentiation, (2) a reduced or absent granular
layer, (3) a dermal inflammatory infiltrate, (4) increased der-
mal vascularity [1, 2]. It affects ≤2 % of the population of
Northern European countries and 0.1 % ~0.3 % of the
Asian population, and its accurate etiology is not well
established [3, 4]. Although the pathogenesis of psoriasis is
not fully understood, evidence suggests that many cyto-
kines, including IL-6, IL-17A, IL17F, IL-22, IL-23 and TNF-
α, are involved and interact as a network in the pathogen-
esis of psoriasis [3, 5–10]. Moreover, T cells, epidermal ker-
atinocytes, dendritic cells (DCs), neutrophils, endothelial
cells and fibroblasts play an important role in the develop-
ment and maintenance of the disease [11].
Currently, the main therapies of psoriasis include psor-
alen and ultraviolet A (PUVA) photochemotherapy, topical
treatment with steroids, retinoid, immunosuppressants, de-
rivatives of vitamin D3, and biological therapies [12–15].
However, most of the therapies have various degrees of side
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effects and require a long duration of administration. Thus,
it is urgent to develop another drug that is effective and
does not induce side effects. EGCG is a possible solution.
The literature has indicated anti-inflammatory, anti-tumor,
antioxidant and anti-ultraviolet radiation effects of EGCG.
For example, polyphenol-60, also known as green tea cat-
echin compound, can down-regulate inflammatory cyto-
kines such as IL-8, which has a therapeutic effect on acne
[16]. EGCG has the function to promote DNA repair and
inhibit inflammasome secretion, which is beneficial in the
treatment of skin tumors [17, 18]. Katiyar et al. confirmed
that the application of TP could significantly reduce the
production of reactive oxygen species (ROS) in skin ex-
posed to ultraviolet light, thereby inhibiting oxidative stress
and oxidative damage [19]. Additionally, researchers have
found that EGCG can reduce the risk of cancer caused by
PUVA therapy, promote the normal differentiation of epi-
dermal keratinocytes and function as an antiangiogenic
compound [20–22]. Therefore, we suspect that EGCG has
potential value in the treatment of psoriasis. There is no re-
search on the other mechanisms of EGCG used in the
treatment of psoriasis. Our research lays a solid foundation
for the treatment of psoriasis with EGCG.
Imiquimod (IMQ) is an agonist of toll-like receptor-7/
8 (TLR-7/8), which is widely used to treat condyloma
acuminata, solar keratosis and basal cell carcinoma.
Topical treatment with IMQ in mice can induce
psoriasis-like skin inflammation through the interleukin
(IL)-23/IL-17 axis, which provides a perfect mouse
model of psoriasis [23]. This study is designed to investi-
gate the effects of EGCG on IMQ-induced psoriasis-like
BALB/c mice. We focused on the change in epidermal
hyperplasia induced by EGCG, dermal infiltrates of T
cells, anti-oxidation, key cytokines including IL-17A, IL-
17 F, IL-22 and IL-23, and the composition of immuno-
cytes in the spleen.
Methods
Mice and treatments
Six to eight week old BALB/c mice with an average
weight of 20–25 g were purchased from the JieSijie Ex-
perimental Animal Company (Shanghai, China) and ran-
domly divided into 7 groups (N = 6). The experiment is
divided into two parts, the first part has three groups
mice, is the external experimental group; the second part
has four groups mice, is the gavage experimental group.
The mice were housed under specific pathogen-free con-
ditions and were fed with formal forage and water ad
libitum in the animal experimental center of Jinshan
Hospital. All experiments were conducted according to
the principles of Guide for the Care and Use of Labora-
tory Animals in China and were approved by the animal
ethics committee of Jinshan Hospital.
Firstly, an area of 5 cm × 4 cm was shaved from the
backs of the three groups, mice. The early intervention
group mice (IMQ +6 EGCG) were applied IMQ and
EGCG glycerin solvent (3 %, 30 mg/ml, glycerin solvent:
50 % glycerin, 50 % normal saline) for 6 consecutive
days; medium-term intervention group mice (IMQ +3
EGCG) were firstly applied IMQ for 3 consecutive days,
then IMQ and EGCG glycerin solvent for 3 consecutive
days; negative control group mice were applied only
IMQ cream for 6 consecutive days. (EGCG: PHR1333-
1 g, Sigma-Aldrich, USA; IMQ: 0.25 g: 12.5 mg; Sichuan
Med-Shine Pharmaceutical Company, LTD, China; gly-
cerin: Sigma-Aldrich, USA) Photos were taken to ob-
serve the changes in the local skin. Then, all the three
groups, mice were killed, and samples of skin were col-
lected for future experiments.
Secondly, the other four groups, mice were conducted
as follows. The normal (N) group and the control (C)
group were applied normal saline (NS) by gavage twice a
day for 3 weeks in a dosage of 0.2 ml/10 g/d. The high-
dose (H) group and the low-dose (L) group were applied
EGCG by gavage twice a day for 3 weeks in a dosage of
300 mg/kg/d and 150 mg/kg/d, respectively. After
3 weeks, an area of 5 cm × 4 cm was shaved from the
backs of all the mice. The control group, the high-dose
group and the low-dose group were applied 42 mg IMQ
cream topically for 6 consecutive days. The normal
group was applied simple IMQ base cream (Shanghai
Dermatology Hospital, China) topically for 6 consecutive
days. Photos were taken on the last day to observe the
changes in the local skin. At the end-point of the experi-
ment, weight was measured. Then, all the four groups,
mice were killed, and samples of blood, skin and spleen
were collected for future experiments.
Scoring severity of skin inflammation
To score the severity of inflammation of the back skin,
an objective scoring system was developed based on the
clinical Psoriasis Area and Severity Index (PASI). Ery-
thema, scales and infiltration were scored independently
on a scale from 0 to 4: 0, none; 1, slight; 2, moderate; 3,
marked; 4, very marked. All scores were evaluated by
two independent personnel. The cumulative score (ery-
thema plus scaling plus infiltration) served to indicate
the severity of inflammation (scale 0–12) [23].
Changes of spleen in mice
The four gavage groups, mice were weighed before
being sacrificed, and then, each spleen was weighed.
We calculated the spleen index (spleen index-spleen
weight/ body weight) to reflect the dynamic body
changes of the mice.
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Histopathological and immunohistochemical
examinations
The skin samples from back lesions from each mouse
were fixed in 4 % paraformaldehyde and embedded in par-
affin for 24–36 hours. Sections (thickness-4 μm) were
stained using hematoxylin and eosin (H&E). The tissue
pathology was observed under a light microscope
(Olympus BX43, Tokyo, Japan). Additionally, the
thickness of the epidermis was measured using the
measurement system of a microscope. For immuno-
histochemistry, the paraffin sections were stained with
primary antibody: the three topical application of
EGCG groups, mice used rabbit anti-mouse PCNA
antibody (KG22625, Kaiji, Jiangsu, China) and rabbit
anti-mouse caspase-14 antibody (PA2104, Boster, CA);
the four treatment with EGCG groups, mice used
rabbit anti-mouse CD3 polyclonal Ab (ab16044,
Abcam, Cambridge, MA, USA). Then anti-ribbit sec-
ondary antibody (KIT9922, Maixin Bio, Fujian, China)
were used. A brown color in epidermis or dermis was
considered as positive staining. The evaluation of IHC
was done by two independent personnel.
Flow cytometry assays of lymphocytes isolated from
mouse spleens
The collected mouse spleens from the four groups were
weighed on an electronic balance and then grinded via
200 mesh screen to obtain single spleen cell suspension.
The spleen cell suspension was lysed by RBC Lysis Buf-
fer. Then, the cells (300–400 g) were spun at 4 °C, and
the pellets were suspended in the appropriate PBS. For
each staining, 1-2 × 109 cells were fluorescently labeled
after incubation in a dark room for 30 min at 4 °C with
the following antibodies (all from Ebioscience, San
Diego, CA, USA): anti-mouse CD3e FITC (no. 11-0031),
anti-mouse CD4 APC (no. 17-0041), anti-mouse CD8a
PE (no. 12-0081), and anti-mouse CD11c PE-Cyanine7
(no. 25-0114). All samples were detected on a flow cyt-
ometer (FACSCalibur; BD Biosciences, CA, USA) and
analyzed with FlowJo ver. 7.6 software.
Assess the levels of inflammatory cytokines including IL-
17A, IL-17 F, IL-22 and IL-23 in plasma
Blood samples were collected from the heart of the four
groups, mice, and plasma was separated. Then, the sepa-
rated plasma was spun at 10000 rpm for 5 minutes at
room temperature, and we aspirated the supernatant. IL-
17A, IL17F, IL-22 and IL-23 levels were assayed using a
Mouse Th17 Milliplex Map Kit (Millipore Corporation,
Billerica, MA, USA). Measurements were performed
using the Bio-Plex MAGPIX Multiplex Reader (Bio-Rad
Laboratories, Hercules, CA, USA).
Activities of SOD, CAT and content of MDA in plasma
Blood samples were collected from the heart of the four
groups, mice and kept in tubes containing heparin so-
dium for 30 min at room temperature. Then, plasma
was separated in a centrifuge (Backman Allegra X-22R
Centrifuge, USA) at 2000 rpm for 20 minutes at room
temperature. The assays of plasma superoxide dismutase
(SOD), catalase (CAT) and malondialdehyde (MDA)
were performed strictly according to the protocol with
colorimetric Diagnostic Reagent Kit from Nanjing
Jiancheng Bioengineering Institute (Nanjing, China).
Statistical methods
Statistics are presented as the means ± standard error of
mean (SEM) and compared using unpaired two-tailed
Student’s t tests or one-way ANOVA. The results were
analyzed using SPSS ver. 22.0 software. P < 0.05 was con-
sidered to be statistically significant. Pictures were pro-
duced using Photoshop ver.13.0 software and Graph Pad
Prism5 software.
Results
EGCG treatment reduces IMQ-induced psoriasiform
lesions of mice
First part: the external experimental group (the three
groups):
It showed that the negative control group (treated with
IMQ only) mice showed erythema, scales and infiltration
from second day on and became more and more obvi-
ous. After 6 days, the mice skin of control group pre-
sented the performance similar to human plaque
psoriasis. But in the early intervention group (IMQ +6
EGCG), the treated skin showed only a few erythema
and thin scales, no obvious infiltration. The medium-
term intervention group (IMQ +3 EGCG) mice had
erythema, scales and infiltration from day two, but after
application of EGCG, the performance were gradually
relieved (Fig. 1a). We evaluated the severity of lesions
with the Psoriasis Area and Severity Index (PASI), which
was adjusted according to the extent of erythema, scales
and infiltration from grade 1–5 in correspondence to 0–
4 scores[23]. We can clearly see the changes of the skin
from the PASI curve (Fig. 1b).
Second part: the gavage experimental group (the four
groups):
The N group had no observable difference from the
previous group. The C group had obvious erythema,
scales and infiltration, whereas the H group and the L
group showed that these features were less severe, espe-
cially in the H group (Fig. 1c). The mice in the C group
had erythema, scales and infiltration on the back skin
from day 2 onward, which became the most obvious on
day 6. However, the H group showed a clear trend of re-
lief of the lesions. The L group had a moderate tendency
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to present with erythema, scales and infiltration (Fig. 1d).
The accumulative score of the H and L group was lower
than that of the C group.
EGCG attenuates the IMQ-induced histological changes of
skin
First part: the external experimental group (the three
groups):
Skin samples were fixed and stained using a standard
hematoxylin and eosin (H&E) method. It was shown in
Fig. 2a–d that the histological changes of the control
group mice exhibited extensive psoriasiform lesions. We
can see marked hyperkeratosis, parakeratosis, modest
acanthosis, elongated rete ridges, and modest dermal in-
flammation. But these changes were significantly allevi-
ated in the experimental groups, especially in the early
intervention group. The thickness of the epidermis in
the control group was 70–150 μm. The value signifi-
cantly decreased in the experimental groups, which was
30–80 μm in the early intervention group and 60–
95 μm in the medium-term intervention group.
Second part: the gavage experimental group (the four
groups):
Results from H&E-stained IMQ-induced psoriasi-
form lesions showed increased parakeratosis,
acanthosis and inflammatory cell infiltration (Fig. 2f ).
EGCG significantly attenuated these changes but did
not clear them completely compared with the N
group (Fig. 2e, g, h). This effect was related to the
dose of EGCG. The effect of the H group was better
than that of the L group (Fig. 2g, h). The thickness
of the epidermis in the C group was 65–145 μm
compared with 6–18 μm in the N group. The value
significantly decreased in the experimental groups,
which was 30–75 μm in the H group and 50–
105 μm in the L group.
Expression of PCNA and caspase-14 in the epidermis of
mice skin of the external experimental group
The control group mice skin exhibited PCNA immuno-
staining almost in all the epidermal layers (Fig. 3a), while
PCNA immunostaining was found primarily in the basal
Fig. 1 IMQ-induced psoriasis-like skin inflammation on the backs of BALB/c mice. (a) The back skin of the three groups displayed different grades
of erythema, scales and infiltration. Photos were taken every day, d1 means one day after application of drugs and so on. (b) Erythema, scales and
infiltration of the skin were identified from the first day on. The cumulative score (erythema plus scaling plus infiltration) was calculated (n = 6, Mean ±
SEM). (c) The back skin of the four groups displayed different grades of erythema, scales and infiltration. Photos were taken after the application of IMQ
for 6 days consecutively. (d) Erythema, scales and infiltration of the skin were identified from the first day on. IMQ, imiquimod; N, the normal group; H,
the high-dose group; L, the low-dose group; C, the control group
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layer of the early intervention group and the medium-
term intervention group (Fig. 3b, c). The percentages of
positive cells stained by PCNA in the three groups were
statistically different (Fig. 3d, P < 0.01). Caspase-14 im-
munostaining in the early intervention group was obvi-
ous compared with that in the control group, and the
medium-term intervention group showed modest stain-
ing (Fig. 3e–g). The percentages of positive cells stained
by caspase-14 in the three groups were statistically dif-
ferent (Fig. 5h, P < 0.01).
EGCG reduces infiltration of T cells in lesions of the
gavage experimental group
T cells are essential in the pathogenesis of psoriasis.
Therefore, we used immunohistochemistry to explore
the effect of EGCG on the infiltration of T cells. In the
control group, we can see the infiltration of T cells in
the lesioned skin. As in the H and L group, the dermal
infiltration of T cells was significantly reduced compared
with the C group (Fig. 3i–l).
Spleen index and the percentages of CD4+T cells, CD8+T cells
and the DCs in spleens of the gavage experimental group
A previous study showed that IMQ could induce spleno-
megaly through systemic effects [23]. We removed the
spleens after topical application of IMQ on mice for 6
consecutive days. A similar result was seen in our study.
The spleens of the C group were significantly bigger
than those of the N group, whereas the spleens of the H
and L group were smaller (Fig. 4a). This finding indi-
cates that EGCG affects splenomegaly induced by IMQ.
We further calculated the spleen index of each group.
The spleen index of the H group was significantly lower
than that of the C group and the L group. The index of
the L group was also significantly lower than that of the
C group (P < 0.01, Fig. 4b).
Psoriasis is an autoimmune inflammatory disease me-
diated by T cells and connected with DCs [24, 25]. Flow
cytometric analysis revealed that the percentage of CD4
+T cells in the C group was significantly decreased com-
pared with that of the N group. EGCG effectively in-
creased the percentage of CD4+T cells in spleens (P <
0.01, Fig. 5b1). In contrast, the percentage of CD11c+
DCs in the C group was significantly increased com-
pared with the N group. EGCG reversed this effect (*P <
0.05, ** P < 0.01, Fig. 5b2). The percentage of CD8+T
cells in the C group was significantly decreased com-
pared with that of the N group. However, there was no
significant difference between the H and L groups and
the C group (P > 0.05, Fig. 5b3). These findings revealed
that EGCG has no effects on CD8+T cells but affects
immunocytes such as CD4+T cells and CD11c+ DCs.
EGCG reduces the expression of inflammatory cytokines
including IL-17A, IL-17 F, IL-22 and IL-23 of the gavage
experimental group
We have stated that IMQ-induced psoriasis-like
skin inflammation in mice is mediated via the IL-
Fig. 2 Respective histopathological changes of each group (H&E staining, original magnification × 400). Scale bar is 50 μm. (a–d) The control
group mice were given IMQ only, and obvious parakeratosis, acanthosis and inflammatory cell infiltration were observed. The changes in the
early intervention group (IMQ + 6EGCG) and medium-term intervention group (IMQ +3 EGCG) skin were eased, especially in the medium-term
intervention group. (e–h)The N group mice received base cream for 6 days, and the epidermis was very thin. The C group mice were given IMQ
instead, and obvious parakeratosis, acanthosis and inflammatory cell infiltration were observed. The H and L group mice were provided EGCG for
3 weeks before given IMQ. The changes in skin were eased compared with the C group, especially in the H group. EGCG, Epigallocatechin-3-
gallate; IMQ, imiquimod; N, the normal group; H, the high-dose group; L, the low-dose group; C, the control group
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23/IL-17 axis. IL-23 secreted by dendritic cells can
induce the proliferation of Th17 cells, which can
activate and secrete IL-17A, IL-17 F, IL-22 and IL-
23 [7, 9, 23]. The expressions of the four inflam-
matory cytokines in plasma were significantly
higher in the C group than in the N group. How-
ever, in the H group and the L group, the expres-
sion was significantly lower than in the C group,
especially in the H group (*P < 0.05, ** P < 0.01,
Fig. 6). The results indicate that EGCG plays an
effective role in reducing inflammatory factors to
alleviate the IMQ-induced inflammatory effects.
Bioactivities of SOD, CAT in plasma and the content of
MDA in plasma of the gavage experimental group
EGCG has been proven to have antioxidant function
[26]. The anti-oxidases such as SOD and CAT can
protect organisms from the damage of oxidative
stress. Therefore, to explore the role of EGCG as an
antioxidant in IMQ-induced psoriasiform changes, we
investigated the activities of SOD and CAT in plasma
and the content of MDA. Fig. 7a–c shows that the
bioactivities of SOD and CAT of the C group were
significantly reduced compared with those of the N
group. However, the content of MDA of the C group
was significantly increased. In contrast, the bioactiv-
ities of SOD and CAT of the H and L groups were
significantly enhanced compared with those of the C
group, and the content of MDA of the H and L
groups was significantly decreased compared with that
of the C group. The antioxidant effect of EGCG dis-
played a dosage effect. The H group demonstrated
better results than the L group.
Discussion
Only a few animal models can imitate the pathogenesis
of human psoriasis. IMQ is a toll-like receptor agonist,
which is used to treat condyloma acuminata, solar kera-
tosis, basal cell carcinoma and other conditions [27, 28].
Van der Fits et al. revealed that IMQ-induced psoriasis-
like inflammation markedly reflected the characteristics
of plaque type psoriasis, which include hyperproliferative
keratinocyte, parakeratosis, absence of a granular layer,
and existence of inflammatory cells consisting of T cells,
Fig. 3 Expression of PCNA and caspase-14, infiltration of T cells were analyzed by immunohistochemistry (original magnification × 400). The
numbers of positive cells were counted per high-power field (HPF) by two independent researchers. (a–d) The expression of PCNA was decreased
in the early intervention group (IMQ + 6EGCG) and medium-term intervention group (IMQ +3 EGCG) compared with that in the control group.
(e–h) The expression of caspase-14 was increased in the early intervention group (IMQ + 6EGCG) and medium-term intervention group (IMQ +3
EGCG) compared with that in the control group. (i- l) T cells in the dermal lesioned skin of the H and L group are significantly less than that in
the C group (n = 6, Mean ± SEM, **P < 0.01). H, the high-dose group; L, the low-dose group; C, the control group
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neutrophils, DCs and vascular proliferation [23]. Ac-
cording to the results, we also successfully created a
mouse model of psoriasis with IMQ (Fig. 1a, c).
Numerous studies have demonstrated that EGCG has
anti-inflammatory, anti-carcinogenic, antioxidant, anti-
aging and anti-mutagenic effects [17, 29]. Stephen Hsu
et al. found that the symptoms of flaky skin in mice were
significantly reduced after taking a bath in water with
0.5 % green tea polyphenol (GTP) [30]. Therefore, we
suspect that EGCG may have a therapeutic effect on
psoriasis. In our study, we revealed that topical applica-
tion or treat with EGCG attenuates IMQ-induced in-
flammation in BALB/c mice, improving its clinical
manifestation and significantly decreasing the adjusted
PASI scores consisting of erythema, scales and infiltra-
tion of the lesions (Fig. 1b, d), which provide further evi-
dence of our conjecture.
Proliferating cell nuclear antigen (PCNA) is a 36 kDa
nuclear non histone protein polypeptide, is one of the
active marker of cell proliferation [31]. One of the basic
features of psoriasis is abnormal proliferation of kerati-
nocytes, and then thick scales form. The results showed
that topical application of EGCG can reduce PCNA ex-
pression, effectively inhibit IMQ-induced abnormal pro-
liferation of epidermal cells and relieve psoriasis-like
appearance (Fig. 3a–d). Caspase-14 is a member of the
caspase family, mainly distributed in the epidermis, is
rare in other tissues, and its main function is to
participate in the terminal differentiation of epidermal
cells and normal skin barrier formation [32]. Obviously,
the skin barrier of psoriasis is damaged, there is abnor-
mal proliferation and differentiation of keratinocytes and
parakeratosis is seen [31]. Our experiments of caspase-
14 immunohistochemical staining in mice damaged
epidermis confirmed the topical application of EGCG ef-
fectively increase the epidermal caspase-14 expression of
IMQ-induced psoriasis-like lesions and early interven-
tion had better effects (Fig. 3e–h). It meant that EGCG
played a role in promoting the normal differentiation of
psoriatic epidermis in mice.
Psoriasis is a T-cell-mediated chronic inflammatory
immune skin disease [33]. The current study found
that T cell is significantly elevated in psoriatic lesions.
The cytokine network, which is activated by T cells,
is an important component in the inflammatory re-
sponse of psoriasis. This experiment found that
EGCG can effectively reduce the expression of CD3
in the skin lesions of mice (Fig. 3i–l), which proved
that the treatment effect of EGCG might reduce the
expression of T cells in mice skin.
The spleen is an important organ in the immune sys-
tem. IMQ induced splenomegaly is related to the sys-
temic effects, whereas EGCG significantly reduced the
spleen index, which was accompanied by the changes in
cellular composition. The percentage of CD4+T cells in
spleens was decreased in the C group mice compared
with the N group (Fig. 5b1). CD11c+ dendritic cells cor-
respond to interstitial dendritic cells in other tissues and
represent the most abundant dendritic cell type in the
dermis [34]. The percentage of CD11c+ dendritic cells
was increased in the C group mice compared with the N
group (Fig. 5b2). This phenomenon was reversed by
EGCG in addition to the remission of IMQ-induced
psoriasis-like inflammation (Fig. 5b1, 2). All these results
suggest that EGCG may regulate the immune function
of psoriasis-like mice through the regulation of CD4+T
cells and CD11c+ dendritic cells. Although CD8+T cells
are important participants in psoriasis, there was no sig-
nificance in the proportion of CD8+T cells (Fig. 5b3).
This finding may be the difference between mouse
model and human psoriasis.
Recently, a group of CD4+T cells found in multiple in-
flammatory diseases and autoimmune diseases, which
can secrete IL-17, has been named: Th17. IL-23 mainly
comes from activated macrophages and dendritic cells,
and it is the key cytokine in promoting the differenti-
ation and development of Th17 cells [1]. Th17 cells and
the cytokines secreted by them, such as IL-17A, IL-17 F,
IL-22 and IL-21, play a role in numerous chronic inflam-
matory diseases including psoriasis [1, 34]. These Th17-
related cytokines can further influence keratinocytes and
other inflammatory cells in the skin, causing local
Fig. 4 Changes in spleens of the four mice groups. (a) EGCG
attenuated splenomegaly induced by topical IMQ. (b) The spleen
index (spleen index = spleen weight/ body weight) was calculated
(n = 6, Mean ± SEM, **P < 0.01). EGCG, Epigallocatechin-3-gallate; N,
the normal group; H, the high-dose group; L, the low-dose group; C,
the control group
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inflammation and proliferation of keratinocytes [7]. All
these findings confirmed the important role of the IL-
23/IL-17 axis in the pathogenesis of psoriasis. As already
mentioned, IMQ-induced psoriasis-like skin inflamma-
tion is related to the IL-23/IL-17 axis. The data shown
in our study revealed that inflammatory cytokines in
plasma including IL-17A, IL-17 F, IL-22 and IL-23 were
reduced with the attenuation of IMQ-induced psoriasis-
like inflammation in the H and L group mice (Fig. 6).
However, the accurate mechanisms of EGCG in redu-
cing these cytokines are undefined. However, we suspect
that the anti-inflammatory effect of EGCG is through
the IL-23/IL-17 axis.
The skin has a complex defense system to protect the
body from harmful environmental and chemical
substances, but excessive exposure can overwhelm the
system, leading to oxidative stress and oxidative damage.
During the energy-producing process of reducing mo-
lecular oxygen to water, reactive oxygen species (ROS)
are formed. ROS are involved in the proliferation, differ-
entiation, apoptosis, immune response and other issues.
An over-production of ROS can take away numerous
ROS-scavenging enzymes, including SOD and CAT [26].
This result is harmful to proteins, lipids, and DNA. Oxi-
dative stress can also be assessed by the level of MDA in
plasma [35]. Healthy skin maintains a dynamic balance
between oxidation and antioxidation, and if this balance
is destroyed, some diseases manifest, including psoriasis
[36]. Previous studies have also found that antioxidants
can improve the symptoms of psoriasis. Moreover, the
Fig. 5 EGCG alters the percentages of CD4+T cells, CD8+T cells and CD11c+ dendritic cells in the spleens with the improvement of IMQ-induced
psoriasis-like inflammation. (a) Flow cytometric analysis of CD4+T cells, CD8+T cells and CD11c+ dendritic cells in the spleens. (b1, b2) The percentages
of CD4+T cells of the two experimental groups are increased, and the percentages of CD11c+ dendritic cells of the two groups are obviously reduced
compared to the C group. The effect of the H group is better than that of the L group (n = 6, Mean ± SEM, *P < 0.05, ** P < 0.01). (b3) No significant
difference in CD8+T cells of spleens between the H group, L group and C group (n = 6, Mean ± SEM, P > 0.05). EGCG, Epigallocatechin-3-gallate; IMQ,
imiquimod; N, the normal group; H, the high-dose group; L, the low-dose group; C, the control group.
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antioxidant function of EGCG has been well established
[37–39]. In our results, the bioactivities of SOD and
CAT in the C group were much lower than that of the
N group, whereas the content of MDA was higher than
that of the N group (Fig. 7). After application of EGCG,
the appearance reversed but did not reach the normal
level. These results were consistent with the morpho-
logical and histological changes of the mice. The results
indicate that EGCG can improve the symptoms of mice
psoriasis by regulating antioxidant factors.
The topical application of EGCG and treatment of
EGCG were used in our study. Moreover, two dose
Fig. 6 EGCG plays a role in the changes of inflammatory factors in plasma. (a, d) EGCG decreases the expression of interleukin (IL)-22 and IL-17 F in plasma,
and these levels were more decreased in the H group than in the L group (n= 6, Mean ± SEM, * P< 0.05, **P< 0.01). (b, c) The relative quantities of IL-23
and IL-17A in the H and L groups are lower than in the C group (n= 6, Mean ± SEM, **P< 0.01). There is no significant difference between the H group
and the L group (n= 6, Mean ± SEM, P> 0.05). EGCG, Epigallocatechin-3-gallate; N, the normal group; H, the high-dose group; L, the low-dose group; C, the
control group.
Fig. 7 EGCG can balance the amount of pro-oxidants and antioxidants in plasma. (a, b, c) The plasma bioactivities of superoxide dismutase (SOD)
and catalase (CAT) of the H and L groups were increased, and that of malondialdehyde (MDA) was decreased compared with the C group (n = 6,
Mean ± SEM, **P < 0.01). EGCG, Epigallocatechin-3-gallate; IMQ, imiquimod; N, the normal group; H, the high-dose group; L, the low-dose group;
C, the control group.
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groups were used as the experimental group in our ex-
periment to explore the different effects between high-
dose EGCG and low-dose EGCG. The high-dose (H)
group and the low-dose (L) group were given EGCG by
gavage twice a day for 3 weeks at a dosage of 300 mg/
kg/d and 150 mg/kg/d, respectively. Most of the data, in-
cluding the clinical and pathological features of mice
skin, spleen index, proportion of CD4+T cells and
CD11c+ dendritic cells in the spleen, and levels of IL-22,
IL-17 F, SOD, CAT and MDA in plasma, showed that
the anti-inflammatory, immune regulatory and antioxi-
dant effects of EGCG of the H group were better than
those of the L group, and early intervention made better
effects (Figs 1, 2, 3, 4, 5, 6 and 7). These findings indi-
cate that these effects of EGCG may be dose dependent.
Conclusion
In conclusion, we demonstrated that EGCG attenuates
IMQ-induced psoriasis-like inflammation; reduces expres-
sion of PCNA; increases expression of caspase-14; reduces
infiltrations of T cells in mice skin; regulates the percent-
ages of CD4+T cells and CD11c+ DC of spleens; down-
regulates the levels of IL-17A, IL17F, IL-22, IL-23 and
malondialdehyde (MDA) in plasma; and increases bioac-
tivities of superoxide dismutase (SOD) and catalase (CAT)
in plasma to treat psoriasis. Moreover, EGCG is extracted
from green tea, which is cheap and easy to obtain. EGCG
is therefore a promising adjuvant intervention in treating
psoriasis in the future.
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